Syed Ali-Aamir Rizvi - 06 Oct 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: Chief Medical Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for Syed Ali-aamir Rizvi
Issuer symbol: RCKT
Transactions as of: 06 Oct 2025
Net transactions value: $0
Form type: 4
Filing time: 08 Oct 2025, 15:39:39 UTC
Previous filing: 22 Sep 2025
Next filing: 13 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rizvi Syed Ali-aamir	Chief Medical Officer	C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY	/s/ Martin Wilson, as attorney-in-fact for Syed Ali-aamir Rizvi	08 Oct 2025	0001897621

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock	Award	$0	+283,018		$0.000000	283,018	06 Oct 2025	Direct	F1
transaction	RCKT	Common Stock	Award	$0	+62,893	+22%	$0.000000	345,911	06 Oct 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Stock Option (right to buy)	Award	$0	+383,854		$0.000000	383,854	06 Oct 2025	Common Stock	383,854	$3.18	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F2	Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries.
F3	Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.